BioCatalystWatch
LGNDWorkspace / LGND / OverviewCompany library
LIGAND PHARMACEUTICALS INC logo

LIGAND PHARMACEUTICALS INC

LIGAND PHARMACEUTICALS INC (LGND)

Website

Price
Market cap
Next catalystFull upLIFT topline results by mid-December 2026Ersodetug — upLIFT · Phase 3 dataCompany source ↗
Cash

Chart & Events

Candle interval

Core Clinical

Upcoming / outlook

  • Timing and evidence

QTORIN rapamycin (PTX-022)

mTOR

PreINDP1P2P3FilingApproved
Upcoming / outlook

  • Timing and evidence

QTORIN rapamycin (PTX-022)

mTOR

PreINDP1P2FilingApproved
Upcoming / outlook

Lasofoxifene

Estrogen receptor

PreINDP1P2P3FilingApproved
Upcoming / outlook

  • Timing and evidence

Volixibat

Ileal Bile Acid Transporter (IBAT)

PreINDP1P2P3FilingApproved
Upcoming / outlook

Angiotensin receptor × Endothelin receptor

Approved

PreINDP1P2P3FilingApproved

Technology Summary

Scientific context

Detailed technology interpretation

Technology advantages

Representative pipeline applications

Disease and market context

Detailed science focus

Background, answer, next evidence

Clinical

Upcoming clinical milestones

Lasofoxifene

Estrogen receptor

PreINDP1P2P3FilingApproved
Upcoming / outlook

  • Timing and evidence

QTORIN rapamycin (PTX-022)

mTOR

PreINDP1P2FilingApproved
Upcoming / outlook

Upcoming / outlook

  • Timing and evidence

QTORIN rapamycin (PTX-022)

mTOR

PreINDP1P2P3FilingApproved
Upcoming / outlook

  • Timing and evidence

Other pipelines

Qarziba

GD2

PreINDP1P2P3FilingApproved
IV ganaxolone

PreINDP1P2P3FilingApproved

PreINDP1P2P3FilingApproved
bevacizumab

PreINDP1P2P3FilingApproved
VK5211

Androgen Receptor (AR)

PreINDP1P2P3FilingApproved
ganaxolone

reproxalap

RASP

PreINDP1P2P3FilingApproved
sugemalimab (CS1001)

PD-L1

PreINDP1P2P3FilingApproved
reproxalap

RASP

PreINDP1P2P3FilingApproved

Partner / License out

PreINDP1P2P3FilingApproved

PreINDP1P2P3FilingApproved
Upcoming / outlook

  • Timing and evidence

QTORIN rapamycin (PTX-022)

mTOR

PreINDP1P2P3FilingApproved
Upcoming / outlook

  • Timing and evidence

QTORIN rapamycin (PTX-022)

mTOR

PreINDP1P2P3FilingApproved

AMPA receptor

Upcoming / outlook

  • Timing and evidence

Approved / commercial

Approved

PreINDP1P2P3FilingApproved

PreINDP1P2P3FilingApproved

Angiotensin receptor × Endothelin receptor

Approved

PreINDP1P2P3FilingApproved

PreINDP1P2P3FilingApproved

RAF

Approved

PreINDP1P2P3FilingApproved

PDE3 / PDE4 / Muscarinic receptor

PreINDP1P2P3FilingApproved
Upcoming / outlook

Qarziba

GD2

Approved

PreINDP1P2P3FilingApproved

History / paused

CD123 × CD3

PreINDP1P2P3FilingApproved
QTORIN rapamycin (PTX-022)

mTOR

PreINDP1P2P3FilingApproved

GCGR

PreINDP1P2P3FilingApproved

CTLA-4

PreINDP1P2P3FilingApproved

PreINDP1P2P3FilingApproved

CD123 × CD3

PreINDP1P2P3FilingApproved

PreINDP1P2P3FilingApproved

Financial position

Net operating cash flow

Source and basis

Company funding outlook

Upcoming milestones

Financial history

Amounts and sources
PeriodCashCurrent investmentsOperatingInvestingFinancing

Source

PeriodCashCurrent investmentsOperatingInvestingFinancing



PeriodCashCurrent investmentsOperatingInvestingFinancing

Source

PeriodCashCurrent investmentsOperatingInvestingFinancing




PeriodCashCurrent investmentsOperatingInvestingFinancing

Source

PeriodCashCurrent investmentsOperatingInvestingFinancing

PeriodCashCurrent investmentsOperatingInvestingFinancing

Source

PeriodCashCurrent investmentsOperatingInvestingFinancing

Source

PeriodCashCurrent investmentsOperatingInvestingFinancing

Source

Annual trends

Reported item

Operating
Investing
Financing

Reported shares and borrowings

Ownership and institutions

Status

Market Reaction / Supply Context

Market Structure

LGND PR & News

PR & News

LGND SEC archive